selegiline hydrochloride (redirected from Apo-Selegiline)

se·leg·i·line hydrochloride (s-lj-ln)

n.

A drug that is an irreversible inhibitor of a specific type of monoamine oxidase, used in conjunction with levodopa and carbidopa to treat patients with Parkinson's disease.

---

selegiline hydrochloride

see l-deprenyl.

---

selegiline hydrochloride

Apo-Selegiline (CA), Eldepryl, Emsam Gen-Selegiline (CA), Novo-Selegiline (CA), Nu-Selegiline (CA), SD Deprenyl (CA), Zelapar

Pharmacologic class: MAO inhibitor (type B)

Therapeutic class: Antidyskinetic

Pregnancy risk category C

FDA Boxed Warning

• Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering using it for MDD in a child or adolescent must balance risk with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
• Drug isn't approved for use in pediatric patients.

Action

Unknown. Thought to increase dopaminergic activity by inhibiting MAO type B in nerve cells, increasing dopamine availability to brain cells.

Availability

Capsules: 5 mg

Tablets: 5 mg

Transdermal system: 6 mg/24 hours, 9 mg/24 hours, 12 mg/24 hours

⊘Indications and dosages

➣ Adjunctive treatment of Parkinson's disease in patients who don't respond to carbidopa-levodopa alone

Adults: 10 mg P.O. daily in divided doses. After 2 to 3 days, attempt to reduce carbidopa-levodopa dosage (typically by 10% to 30%).

➣ Major depressive disorder

Adults: Initially, apply 6 mg/24 hours patch; increase in dose increments of 2 mg/24 hours up to a maximum dose of 12 mg/24 hours at intervals of no less than two weeks, if needed.

Off-label uses

• Initial therapy for Parkinson's disease
• Alzheimer's disease
• Narcolepsy
• Adjunct in schizophrenia

Contraindications

• Hypersensitivity to drug or its components
• Concurrent meperidine therapy

Precautions

Use cautiously in:
• patients receiving tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SRRIs), or dextromethorphan, carbamazepine, and analgesics such as tramadol, methadone, and propoxyphene
• patients with pheochromocytoma
• elderly patients
• pregnant or breastfeeding patients
• children.

Administration

• Give with breakfast and lunch, but restrict foods high in tyramine (such as aged cheese, red wine, yogurt, and smoked high-protein foods).
☞ Don't give within 14 days of TCAs or SSRIs (5 weeks for fluoxetine because of its long half-life).
• Apply patch to dry, intact skin on the upper torso (below the neck and above the waist), upper thigh, or the outer surface of the upper arm once every 24 hours.

Route	Onset	Peak	Duration
P.O.	Unknown	0.5-2 hr	Unknown

Adverse reactions

CNS: agitation, anxiety, bradykinesia, chorea, confusion, delusions, depression, dizziness, hallucinations, headache, dyskinesias, increased akinetic involuntary movements, insomnia, lethargy, light-headedness, loss of balance, syncope, vivid dreams

CV: orthostatic hypotension, hypertension, new or increased angina, palpitations, arrhythmias

GI: nausea, diarrhea, abdominal pain, dry mouth

GU: urinary retention

Musculoskeletal: leg pain, low back pain

Other: generalized aches, weight loss

Interactions

Drug-drug. Adrenergics: increased pressor response

Buspirone: elevated blood pressure

Dextromethorphan: brief episodes of psychosis or bizarre behavior

Levodopa: increased adverse reactions to levodopa

Meperidine and analgesics such as tramadol, methadone, and propoxyphene: stupor, muscle rigidity, severe agitation, fever, death

Other MAO inhibitors: hypertensive crisis

SSRIs, TCAs: severe mental status changes, CNS toxicity (with possible hyperpyrexia and death)

Drug-food. Tyramine-rich foods (such as aged cheese, red wine, yogurt, smoked high-protein foods): hypertensive crisis

Drug-herbs. Cacao: vasopressor effects

Ginseng: headache, tremor, mania

St. John's wort: life-threatening adverse reactions

Patient monitoring

• Monitor vital signs and cardiovascular status.
• Assess neurologic status and motor function. Institute safety measures as needed to prevent injury.
• Monitor weight and fluid intake and output.
• Monitor CBC and liver and kidney function tests.

Patient teaching

• Tell patient he may take capsules or tablets with or without food, but he should avoid foods and beverages high in tyramine. Provide a list of these foods and beverages.
• Inform patient to avoid tyramine-rich foods and beverages beginning on the first day of application of 9mg/24hours- or 12mg/24hours-patch and continue to avoid these foods and beverages for two weeks after a dose reduction to the 6mg/24hours-patch or following the discontinuation of the 9mg/24hours- or 12mg/24hours-patch.
• Instruct patient (and caregiver as appropriate) to monitor neurologic status and motor function and to institute safety precautions as needed to prevent injury.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
• Tell patient (or caregiver) that drug may cause serious interactions with many drugs. Instruct him to tell all prescribers he's taking it.
• Tell patient not to use St. John's wort without consulting with prescriber.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.